LICENSE AGREEMENT BY AND BETWEEN GALDERMA HOLDING SA AND SOL-GEL TECHNOLOGIES LTD.License Agreement • April 4th, 2022 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York
Contract Type FiledApril 4th, 2022 Company Industry JurisdictionTHIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 21, 2021 (“Effective Date”) between Sol-Gel Technologies Ltd., with a principal place of business at 7 Golda Meir St., Ness Ziona 7403620, Israel (“Sol-Gel”), and Galderma Holding SA, with a principal place of business at Rue d'Entre-deux-Villes 10, 1814 La Tour-de-Peilz, Switzerland (“Galderma”). Sol-Gel and Galderma may be referred to herein individually as a “Party” and collectively as the “Parties.”
Contract Manufacturing AgreementContract Manufacturing Agreement • April 4th, 2022 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York
Contract Type FiledApril 4th, 2022 Company Industry JurisdictionCustomer Galderma, or following any termination of this Agreement by Galderma pursuant to clause 16 (Termination), Sol-Gel or its designated Affiliate or licensee, in accordance with clause 16.5 (Effect of Termination as to Galderma).
TERMINATION AGREEMENT ([***])Termination Agreement • April 4th, 2022 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York
Contract Type FiledApril 4th, 2022 Company Industry JurisdictionThis Termination Agreement ("Agreement") is entered into as of November 3, 2021 ("Effective Date"), between Padagis Israel Pharmaceuticals Ltd, a limited liability company organized in Israel ("Padagis"), and Sol-Gel Technologies Ltd., a limited liability company organized in Israel ("Sol-Gel"). Padagis and Sol-Gel are individually referred to as a "Party" and collectively referred to as the "Parties. "
TERMINATION AGREEMENTTermination Agreement • April 4th, 2022 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York
Contract Type FiledApril 4th, 2022 Company Industry JurisdictionThis Termination Agreement ("Agreement") is entered into as of November 3, 2021 ("Effective Date"), between Padagis Israel Pharmaceuticals Ltd, a limited liability company organized in Israel ("Padagis"), and Sol-Gel Technologies Ltd., a limited liability company organized in Israel ("Sol-Gel"). Padagis and Sol-Gel are individually referred to as a "Party" and collectively referred to as the "Parties. "